Phage therapy for multidrug-resistant Acinetobacter baumannii.
- Author:
Jia WU
1
;
Jun WANG
2
Author Information
- Publication Type:English Abstract
- Keywords: Acinetobacter baumannii; multidrug-resistant; phage; phage-derived enzymes
- MeSH: Acinetobacter baumannii/drug effects*; Drug Resistance, Multiple, Bacterial; Phage Therapy/methods*; Acinetobacter Infections/microbiology*; Humans; Bacteriophages/physiology*; Anti-Bacterial Agents/pharmacology*
- From: Chinese Journal of Biotechnology 2025;41(6):2256-2274
- CountryChina
- Language:Chinese
- Abstract: Acinetobacter baumannii is a Gram-negative opportunistic pathogen widely distributed in hospital settings. It can survive for a long time and cause a variety of infections, including pneumonia, septicemia, urinary tract infections, and meningitis. The bacterium demonstrates extensive resistance, particularly to critical antibiotics like carbapenems and polymyxins, posing a serious threat to the recovery of severely ill patients. Carbapenem-resistant A. baumannii has been designated as a pathogen of critical priority on the World Health Organization (WHO) Bacterial Pathogen Priority List, requiring urgent development of new therapeutic agents. Phages, as a novel biological control approach, exhibit substantial potential in combating A. baumannii infections due to their specific ability to infect and lyse bacteria. This review highlights the application and potential of phages and phage-derived enzymes against multidrug-resistant A. baumannii, considering the epidemiological trends of A. baumannii in China, with the aim of providing innovative insights and strategies for phage therapy of drug-resistant bacterial infections.
